XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Nonvested Restricted Shares
A summary of changes in the Company’s nonvested restricted shares for the nine months ended September 30, 2024 and September 30, 2023 follows:
SharesWeighted-Average
Grant-Date
Fair Value, per share
Nonvested at January 1, 2024
52,195 $18.75 
Granted
30,650 11.70 
Vested
(29,835)(18.24)
Forfeited
(1,125)(16.05)
Nonvested at September 30, 2024
51,885 $14.93 
SharesWeighted-Average
Grant-Date
Fair Value, per share
Nonvested at January 1, 2023
22,000 $21.52 
Granted
46,175 18.30 
Vested
(13,935)(20.01)
Forfeited
(1,865)(19.38)
Nonvested at September 30, 2023
52,375 $18.75 
Schedule of Activity in the Equity Plan
A summary of the activity in the Equity Plan for the nine months ended September 30, 2024 and September 30, 2023 follows:
SharesWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2024
367,033 $15.68 
Forfeited
(2,970)(15.56)
Outstanding at September 30, 2024
364,063 $15.57 4.92$— 
Vested and exercisable at September 30, 2024
349,385 $15.71 4.88$— 
SharesWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2023
405,688 $15.67 
Exercised
(30,375)(15.71)
Forfeited
(7,980)(15.51)
Outstanding at September 30, 2023
367,333 $15.67 5.93$— 
Vested and exercisable at September 30, 2023
323,022 $15.79 5.78$—